Buzz on the Street Show: Defense Metals (OTCQB: DFMTF) (TSX-V: DEFN) Plans for Wicheeda Expansion | Financial Buzz Buzz on the Street Show: Defense Metals (OTCQB: DFMTF) (TSX-V: DEFN) Plans for Wicheeda Expansion financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Sponsored Content Release
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.Finan
Sponsored Content Release
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.Fina
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “U.S. Well Services Set to Move Towards Full Electrification of its Portfolio”
U.S. Well Services (NASDAQ: USWS) surged over 24% in premarket trading after the company announced its move towards full electrification of its portfolio.
The company announced its commitment to becoming an all-electric hydraulic fracturing services provider and expects to have fully exited the diesel frac market by the end of Q4 2021, thus becoming the first publicly-traded, pure-play electric completions services provider.
U.S. Well Services, Inc. is a leading provider of hydraulic fracturing services and a market leader in electric fracture stimulation. The Company’s patented electric frac technology provides one of the first fully electric, mobile well stimulation systems powered by locally-supplied natural gas, including field gas sourced directly from the wellhead. The Company’s electric frac technology dra
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Pieris Pharmaceuticals, Inc. Climbs Following Respiratory and Ophthalmology Collaboration with Genentech”
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) surged over 21% in premarket trading after the company announced a respiratory and ophthalmology collaboration with Genentech.
The company has entered into a multi-program research collaboration and license agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris’ proprietary Anticalin® technology.
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment.